Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
Authors:
- Doyeun OhDODoyeun Oh
- Ross I. BakerRBRoss I. Baker
- on behalf of the Korean TTP Registry InvestigatorsOIon behalf of the Korean TTP Registry Investigators
Open Access
- 30 September 2019
- journal article
- research article
- Published by Springer Nature in Blood Research
- Vol. 54 (3) , 218-228
Abstract
Oh J, et al. Blood Res. 2019 Sep;54(3):218-228. https://doi.org/10.5045/br.2019.54.3.218Keywords
This publication has 28 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-ThrombosisPLOS ONE, 2013
- Complement activation in thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2012
- Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical ManifestationsHematology-American Society Hematology Education Program, 2011
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center ExperiencePLOS ONE, 2010
- Survival and relapse in patients with thrombotic thrombocytopenic purpuraBlood, 2010
- Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathiesThrombosis and Haemostasis, 2005